Pulse 2.0
Cover art for Arcturus Meiji Investment Details

Arcturus Meiji Investment Details

Arcturus Therapeutics secures $50m Meiji investment at 80% premium for mRNA tech.

By ·

Nov 17, 2026

3 cards · 30s · tap to begin

From · · · 30s

Arcturus Meiji Investment Details

Arcturus Therapeutics secures $50m Meiji investment at 80% premium for mRNA tech.

In brief

Arcturus Therapeutics secures $50m Meiji investment at 80% premium for mRNA tech. Arcturus Therapeutics received $50 million from Meiji Seika Pharma at 80% premium for its mRNA platform, accelerating cystic fibrosis and ornithine transcarbamylase deficiency treatments. Originally reported by Pulse 2.0.

Investment Terms

Meiji purchases Arcturus securities at $20.27 per share, an 80% premium, representing 7.9% of shares.

Technology License

Arcturus licenses ARCT-154 technology for an undisclosed therapeutic area.

Pandemic Partnership

Meiji and Arcturus agree to potential pandemic preparedness collaboration in Japan.

The key point

Arcturus Therapeutics received $50 million from Meiji Seika Pharma at 80% premium for its mRNA platform, accelerating cystic fibrosis and ornithine transcarbamylase deficiency treatments.

Read the original on Pulse 2.0

Read the TL;DR — this story on one card.

How we make summaries

React

Sign in to react and comment.

Comments (0)

Life is short. Keep it sweet. Respect others' opinions and be kind!

    Recommended next

    More decks on arcturus therapeutics and related topics.